Savient Pharmaceuticals (SVNT) 10-Q 2013 Q3 Quarterly report

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Savient Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Richard Crowley, Co-President and Chief Operating Officer, Philip K. Yachmetz, Co-President and Chief Business Officer, and John P. Hamill, Co-President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

SAVIENT PHARMACEUTICALS , INC. (Registrant)
By:	/s/    Richard Crowley
	Richard Crowley
	Co-President and Chief Operating Officer (Principal Executive Officer)
By:	/s/    Philip K. Yachmetz
	Philip K. Yachmetz
	Co-President and Chief Business Officer (Principal Executive Officer)
By:	/s/    John P. Hamill
	John P. Hamill
	Co-President and Chief Financial Officer
	(Principal Financial Officer)

November 14, 2013